Spero Therapeutics Operating Income

Spero Therapeutics (SPRO) currently reports a operating income of $7.2M as of March 2026. That compares with $-78M in the prior-year period — up 109.2% year over year. Use the charts on this page to explore Spero Therapeutics's operating income history and peer comparisons.

Spero Therapeutics's operating income increased from $-78M to $7.2M — a 109.2% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Spero Therapeutics reported $7.2M in operating income as of March 2026. That compares with $-78M in the prior-year period — up 109.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $7.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Spero Therapeutics, and consider following SPRO for alerts when major investors trade the stock.

Spero Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $7.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPRO with unrelated industries.